Entering text into the input field will update the search result below

SIGA begins clinical program to expand use of smallpox drug for post-exposure prevention

Mar. 02, 2022 8:30 AM ETSIGA Technologies, Inc. (SIGA)By: Ravikash, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

SIGA Technologies (NASDAQ:SIGA) said it began a clinical program to support a U.S. FDA label expansion for Post-Exposure Prophylaxis (PEP) for oral TPOXX, which was approved in July 2018 to treat smallpox.

The first

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.